ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FUM Futura Medical Plc

39.70
-1.60 (-3.87%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.60 -3.87% 39.70 39.40 40.00 41.30 39.55 41.30 378,350 16:35:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 3.1M -6.51M -0.0217 -18.43 120.28M
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 41.30p. Over the last year, Futura Medical shares have traded in a share price range of 24.10p to 67.00p.

Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £120.28 million. Futura Medical has a price to earnings ratio (PE ratio) of -18.43.

Futura Medical Share Discussion Threads

Showing 14026 to 14042 of 21550 messages
Chat Pages: Latest  562  561  560  559  558  557  556  555  554  553  552  551  Older
DateSubjectAuthorDiscuss
13/10/2022
17:23
Lets just talk about side effects from now on - I could go through them one by one if you insist

puffy face from water retention
excessive thirst
cough
an increase in the amount of phlegm
vomiting
difficulty swallowing
an increased need to urinate often

Not much doubt what I would use - virtually anything but a substance causing all this trouble
I think even you would do the same - just think of your reaction as you 'rubbed' it in - being careful not to exceed 15 seconds allowed in the trials

mikethebike4
13/10/2022
16:07
Medical device gels like Med3000 are only really competitors to other medical devices like lubricants or even other medical devices like Giddy for ED. The all just have mechanical modes of action including Med3000 abd have only had to meet the low thresholds of the same medical device studies!

The ED medical device market is not the same as the ED drugs market.





Devices are subject to weaker standards than drugs because they are regulated under a different law. The Medical Device Amendments of 1976 was intended to encourage innovation while allowing for a range of review standards based on risk, according to legal expert Richard A. Merrill. An array of corporate lobbying has since prompted Congress to ease regulations and make it easier for devices to get the FDA OK

Journalists need to scrutinize the claims
Journalists have a responsibility to report this lack of evidence, but they often dont. Investigative journalist Jeanne Lenzer, who wrote a book about the under-regulated medical device industry, says more dogged reporting is needed: We really dont know what we are getting with many of these devices

Ninety-nine percent of devices never have to provide clinical data, thanks in part to the 2002 Medical Devices User Fee Act, which requires the FDA to use the least burdensome route

For the few devices subject to a scientific review, the quality standards are flimsy. Randomized controlled trials, the gold standard, are infrequent. Most studies are unblinded, and thus prone to bias. The FDA settles for loosely defined reasonable assurance’that a device is safe and effective, versus its higher standard of substantial evidence for drugs, which require studies with comparison groups that didnt receive the same treatment. Thus, data that would never be sufficient to support the approval of a drug can result in the approval of a device used to treat the same condition, potentially diverting patients from effective drugs to less-effective devices.



De Novo-winning devices often lack effectiveness data, analysis shows

lbo
13/10/2022
14:11
No it’s not competition and only rampers believe that it is. Its not even in the same class. Viagra is a drug with proven effects beyond a placebo. MED3000 is just a medical device with no proven effect ever beyond a placebo!

Ans if rubbing in a sham MED30000 gel works then rubbing in any similar alcohol, water and glycol gel will also work work for that man!



Kama Sutra Intensify Plus Female Arousal Gel Cooling 15 ml

Ingredients: Water, Propylene Glycol, Denatured Alcohol

Here is the Med3000 patent application and the ingredients of Med3000! Alcohol, water and Gylcol! L



The composition of the invention contained: ethanol: 33%; water: 35%; glycerol: 24%; propylene glycol: 6%; Carbopol® Ultrez 10: 1%. pH was adjusted to 5.25 with potassium hydroxide solution. The ethanol used in the manufacture of the composition was absolute ethanol (i.e. 100% ethanol free from water) such that the final composition contained 33% of pure ethanol. If a lower grade of ethanol was used which contained impurity amounts of water (e.g. 96% ethanol), then the amount used would have to be adjusted to ensure the final composition contained the correct amount of the components, i.e. 33% pure ethanol and 35% water.

lbo
13/10/2022
13:33
Even the market analysts know all Futura have done is paid for the research to allow Reckitt also claim its class 2 medical device lubricants/arousal gels are also placebo treatments for Psychogenic ED!



˜You are the active ingredient’




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

lbo
12/10/2022
19:26
Really mike! And 4 more years later with nothing to show but yet another medical device. And not even a class 3 device with ancillary drug. But just one made from alcohol and water and equivalent to basically any class 2 medical device cooling lubricant/arousal gel. You say there is no motive for negativity! Its nearly a wonder why Terence dumped those shares!!! ROFLMAO

mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141

I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.
I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares
Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !

lbo
12/10/2022
17:57
LBO = motive for negativity ?
mikethebike4
12/10/2022
15:28
Interesting part of today's RNS are the dates! 5. Date on which the threshold was crossed or reached (vi) : 02/06/20216. Date on which issuer notified 10/10/2022
lbo
12/10/2022
15:08
freddie why did you compare Futura to Enron? LOL

freddievas - 27 Sep 2021 - 14:15:44 - 9974 of 13655

Enron was worth North of $60billion....a bit of a way to go yet!


freddievas - 08 May 2019 - 12:03:56 - 5324 of 13655

pump and dump I fear.

freddievas - 21 Mar 2018 - 10:07:21 - 3982 of 13656

"Futura a winner for 2015" says it all really.

lbo
12/10/2022
14:12
Should have known better. Filtered anyway.
freddievas
12/10/2022
12:50
Hey Broomrigg how come you are not posting your more buyers then sellers posts today? Whats that other important stock market saying. Its better to travel then arrive. Could that be the case with the realisation its just a De Novo medical device application! LOL

FOR EVERY BUYER THERE MUST BE A SELLER



Jay: What I meant was, where did the shares you purchased come from? They didn’t come out of thin air. Someone had to sell them to you. The market has two types of investors: individuals like you and me, and institutional investors such as pension funds, mutual funds and hedge funds. Do you believe the seller was more likely another individual investor like you? Or was the seller more likely one of those institutional investors?
Haden: I would guess the seller was another individual investor.
Jay: That’s incorrect. Since today institutional investors do about 90 percent of all trading, there’s about a 90 percent chance the seller was an institution. Since we now agree the underlying reason you bought the stock was that you believed it would outperform the market, we can also agree the underlying reason the institutional investor sold the stock was that it believed the stock would underperform the market. If that were not the case, it would have continued to hold the stock. Correct?
Haden: I guess so.
Jay: Okay. You believed it would outperform the market, and the institutional investor believed it would underperform. How many of you can be correct?
Haden: Just one.
Jay: If you’re being perfectly honest with yourself, who do you believe had more knowledge about the company—you or the institutional investor?
Haden: I’d have to say the institutional investor.

lbo
12/10/2022
11:15
How ironic mike you now talk of ‘misguided intent’! So where was the ˜initial upfront payment’ from Cooper in the results!? LOL


mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141
Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says


mikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141
Company is massively over valued if you go by 'concrete' results !


mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141
I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.
I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares
Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !


mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591
"A couple of decent deals and will be back off to the races."
Do you have any idea of how long shareholders have been using these words


mikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591
As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated.
All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day!


mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713
why should it be any different this time when you've still got the same useless lot running the show

mikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641
I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-life
And where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remuneration
I just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick

lbo
12/10/2022
10:59
No he was ever only an avatar of an obsession with misguided intent
mikethebike4
12/10/2022
10:37
Gosh, I wonder if LBO is still alive!
freddievas
07/10/2022
16:10
Fair point.
joestalin
07/10/2022
16:10
Fair point.
joestalin
07/10/2022
09:03
Joe I am also worried about your and Dontshoutatonce mental health! You seem to have forgotten what you used to say about Futura and we know dontshoutatonce is seriously down on his shares

Dontshoutatonce - 04 Jun 2018 - 17:36:54 - 4248 of 13648

Sleeping is the word but no beauty. I've been with FUM for about 10 years or more and it's not worth my selling as I'm down a big %


JoeStalin - 30 Sep 2019 - 10:07:37 - 5937 of 10774
FUTURA a winner for 2015 - says it all!


JoeStalin - 18 Jul 2018 - 09:00:46 - 4354 of 10775
'jam tomorrow' is a very easy promise to make.


JoeStalin - 22 Jun 2018 - 14:12:24 - 4288 of 10775
What's another year after all?
At FUM, time is measured in decades.


JoeStalin - 25 Apr 2018 - 16:07:34 - 4147 of 10775
There seems to be an unlimited number of ways of saying "Jam tomorrow".


JoeStalin - 21 Mar 2018 - 13:50:44 - 3985 of 10775
A lifestyle company, but not for the shareholders.

lbo
06/10/2022
19:48
All Futura have done is also allow Reckitt to sell lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that Med3000 itself has no proven effect in ED beyond a placebo. As it has not proven efficacy in a placebo controlled study or even against any standard cooling lubricant/arousal gels.




‘You are the active ingredient’




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction




For many, whether or not placebo use is ethical depends partly on whether patients are being deceived and whether there is a known better treatment.
A clinician who doesn’t deceive a patient, and who provides a placebo for something for which there is no known treatment, such as irritable bowel syndrome, might be ethically OK, says Jeremy Howick, of the Department of Primary Health Care Sciences, at the University of Oxford, and lead author of the Plos One study. “But there is no evidence that this company is enhancing care. What they’ve ve been doing is completely unethical

lbo
Chat Pages: Latest  562  561  560  559  558  557  556  555  554  553  552  551  Older

Your Recent History

Delayed Upgrade Clock